Seer Bio
IPOUnbiased, deep, rapid proteomics at scale
Public · Redwood City · Founded 2017 · $93.0M raised
- Headquarters
- Redwood City
- Employees
- 51–200
- Founded
- 2017
- Business Model
- B2B
- Website
- seer.bio
- Total Funding
- $93.0M
- Last Round
- $55.0M Series DJul 2020
- Rounds
- 3
- Type
- Public
About
Seer is a life sciences company commercializing the Proteograph Product Suite, a disruptive platform for large-scale, unbiased proteomics. Its nanoparticle-based technology enables researchers to access the breadth and depth of the proteome from plasma samples, advancing cancer, cardiovascular, and neurodegenerative disease research. Seer is publicly traded on Nasdaq (SEER) and headquartered in Redwood City, California.
Summary
Seer Bio is a Biotech company based in Redwood City, founded in 2017. It has raised $93.0M in total across 3 rounds, most recently a $55.0M Series D round in Jul 2020. Investors include Invus, Maverick Ventures and J.P. Morgan.
Tech & App Stack
11 technologies & apps tracked
Create a free account — 25 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — 25 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Dec 2020
Sign up to see all 4 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.